News

Levi & Korsinsky, a law firm has filed lawsuit in Delaware Chancery court challenging the proposed acquisition of Sepracor. The complaint arises out of the announcement by Sepracor

AgraQuest and Alpharma Animal Health have agreed to terms for a supply agreement in which AgraQuest will supply their strain of Bacillus subtilis. This input will be used

Germany-based Merck has reported new data from a post-hoc analysis of the two-year (96-week) placebo-controlled CLARITY phase III trial, using a short-course of Cladribine Tablets. Cladribine Tablets (the

Genzyme has reported that a four-year follow-up data from its completed phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation

Takeda and its wholly-owned subsidiary, Millennium Pharmaceuticals have initiated stage II of a phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer. TAK-700 is a

Access Pharmaceuticals (Access) has entered into an agreement with a commercial manufacturer, Accupac, to produce its FDA-approved MuGard for North American distribution. MuGard is a novel, ready-to-use mucoadhesive

The FDA has accepted for review Merz Pharmaceuticals’ (Merz) premarket approval (PMA) application for Belotero Balance. Belotero Balance is a hyaluronic acid-based monophasic gel dermal filler that utilizes

American Oriental Bioengineering (AOBO) has launched a new over-the-counter (OTC) product – YuYeQingHuo Capsules (YYQH). YYQH will be manufactured by the company’s Boke subsidiary. It will be marketed

Sanofi-aventis has reported the results of a phase II study with teriflunomide, a novel orally available immunomodulatory therapy for multiple sclerosis (MS). Teriflunomide is currently being explored in